A Cross-Sectional, Questionnaire-Based Study on Drug Treatment Awareness in Schizophrenia Patients and Caregivers: An Unexplored Avenue.
Awareness
Caregivers
Drug treatment
Insight
Schizophrenia
Journal
Indian journal of psychological medicine
ISSN: 0253-7176
Titre abrégé: Indian J Psychol Med
Pays: United States
ID NLM: 7910727
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
ppublish
Résumé
Schizophrenia is associated with high relapse rates, and medication nonadherence is a major factor contributing toward relapse. Since medication adherence and treatment awareness are linked, an alarming need was felt to evaluate the level of drug treatment awareness in patients who have schizophrenia. Besides, patients who have schizophrenia are often dependent on their caregivers for medications. Hence, the current study was also designed to look into drug treatment awareness among caregivers. This was a cross-sectional, questionnaire-based study. Patients diagnosed with schizophrenia as per A total of 166 patients and 157 caregivers were enrolled. Mean drug awareness scores among patients and caregivers did not show statistically significant differences (P= 0.22). Mean ± SD DTAQ awareness scores in patients and caregivers were 12.57 ± 1.81 and 12.84 ± 1.91, respectively. The majority of patients and caregivers (> 90%) possessed awareness in domains related to past medication records and in that of re-visit/re-contact instructions. Awareness was least commonly seen in relation to side effects of medications and details of the prescribed medications, where only about 50% of patients and caregivers possessed awareness. No clinically significant correlation was found between sociodemographic factors and drug treatment awareness scores. Drug treatment awareness in patients and caregivers was comparable and was not reliant on the sociodemographic factors. Special interventions should be conducted to raise drug treatment awareness among patients having insight and their caregivers.
Sections du résumé
Background
UNASSIGNED
Schizophrenia is associated with high relapse rates, and medication nonadherence is a major factor contributing toward relapse. Since medication adherence and treatment awareness are linked, an alarming need was felt to evaluate the level of drug treatment awareness in patients who have schizophrenia. Besides, patients who have schizophrenia are often dependent on their caregivers for medications. Hence, the current study was also designed to look into drug treatment awareness among caregivers.
Methods
UNASSIGNED
This was a cross-sectional, questionnaire-based study. Patients diagnosed with schizophrenia as per
Results
UNASSIGNED
A total of 166 patients and 157 caregivers were enrolled. Mean drug awareness scores among patients and caregivers did not show statistically significant differences (P= 0.22). Mean ± SD DTAQ awareness scores in patients and caregivers were 12.57 ± 1.81 and 12.84 ± 1.91, respectively. The majority of patients and caregivers (> 90%) possessed awareness in domains related to past medication records and in that of re-visit/re-contact instructions. Awareness was least commonly seen in relation to side effects of medications and details of the prescribed medications, where only about 50% of patients and caregivers possessed awareness. No clinically significant correlation was found between sociodemographic factors and drug treatment awareness scores.
Conclusion
UNASSIGNED
Drug treatment awareness in patients and caregivers was comparable and was not reliant on the sociodemographic factors. Special interventions should be conducted to raise drug treatment awareness among patients having insight and their caregivers.
Identifiants
pubmed: 35655976
doi: 10.1177/02537176211056358
pii: 10.1177_02537176211056358
pmc: PMC9120996
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-144Informations de copyright
© 2021 Indian Psychiatric Society - South Zonal Branch.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Iran J Psychiatry. 2015 Sep;10(4):239-45
pubmed: 27006669
Neuropsychiatr Dis Treat. 2018 Jan 04;14:185-191
pubmed: 29379291
Patient Prefer Adherence. 2017 Mar 03;11:449-468
pubmed: 28424542
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Asian J Psychiatr. 2019 Oct;45:74-80
pubmed: 31520884
Indian J Psychol Med. 2013 Jan;35(1):60-6
pubmed: 23833344
BMJ. 2000 Aug 5;321(7257):384-5
pubmed: 10991571
Br J Clin Pharmacol. 2009 Jun;67(6):676-80
pubmed: 19594537
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18
pubmed: 24167693
Psychiatry Res. 2017 Nov;257:315-321
pubmed: 28800510
World Psychiatry. 2018 Oct;17(3):341-356
pubmed: 30192094
Int J Soc Psychiatry. 2020 Jun;66(4):361-372
pubmed: 32126902
Neuropsychiatr Dis Treat. 2015 May 08;11:1161-7
pubmed: 26056450
Prev Chronic Dis. 2005 Jan;2(1):A13
pubmed: 15670466
Clin Transl Sci. 2011 Oct;4(5):332-7
pubmed: 22029804
Bipolar Disord. 2010 Sep;12(6):627-37
pubmed: 20868461
Saudi J Anaesth. 2017 May;11(Suppl 1):S80-S89
pubmed: 28616007
Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):27-38
pubmed: 28756468
Neuropsychiatr Dis Treat. 2019 Apr 23;15:967-976
pubmed: 31118637
Patient Educ Couns. 2013 Oct;93(1):73-9
pubmed: 23856552
Acta Psychiatr Scand. 1994 Jan;89(1):62-7
pubmed: 7908156
Pharm Pract (Granada). 2018 Apr-Jun;16(2):1174
pubmed: 30023029
Clin Rehabil. 1998 Jun;12(3):187-99
pubmed: 9688034
Eur Arch Psychiatry Clin Neurosci. 2000;250(6):292-303
pubmed: 11153964
PLoS One. 2015 Mar 27;10(3):e0120560
pubmed: 25816353
Indian Pediatr. 2017 Oct 15;54(10):867-870
pubmed: 29120335
J Family Med Prim Care. 2014 Jan;3(1):3-4
pubmed: 24791227
Indian J Psychol Med. 2015 Jan-Mar;37(1):5-11
pubmed: 25722504
Am J Psychiatry. 2005 Dec;162(12):2382-4
pubmed: 16330606